Publication Author: Sullivan_Sean

• Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults.

  Kuznik A, Bégo-Le-Bagousse G, Eckert L, Gadkari A, Simpson E, Graham CN, Miles L, Mastey V, Mahajan P, Sullivan SD. Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults. Dermatol Ther (Heidelb). 2017 Dec;7(4

  rakerr2

  December 1, 2017

• Favorable and publicly funded studies are more likely to be published: a systematic review and meta-analysis.

  Canestaro WJ, Hendrix N, Bansal A, Sullivan SD, Devine EB, Carlson JJ. Favorable and publicly funded studies are more likely to be published: a systematic review and meta-analysis. J Clin Epidemiol. 2017 Dec;92:58-68. doi: 10.1016/j.jclinepi.2017.08.004.

  rakerr2

  December 1, 2017

• A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study.

  Bansal A, Sullivan SD, Hershman DL, Lyman GH, Barlow WE, McCune JS, Ramsey SD. A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients

  rakerr2

  July 1, 2017

• Impact of a value-based formulary in three chronic disease cohorts.

  Yeung K, Basu A, Marcum ZA, Watkins JB, Sullivan SD. Impact of a value-based formulary in three chronic disease cohorts. Am J Manag Care. 2017 Mar;23(3 Suppl):S46-S53. doi: 87035.

  rakerr2

  March 1, 2017

• Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.

  Yeung K, Basu A, Hansen RN, Watkins JB, Sullivan SD. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures. Med Care. 2017 Feb;55(2):191-198. doi: 10.1097/MLR.0000000000000630.

  rakerr2

  February 1, 2017

• Toward a Hedonic Value Framework in Health Care.

  Basu A, Sullivan SD. Toward a Hedonic Value Framework in Health Care. Value Health. 2017 Feb;20(2):261-265. doi: 10.1016/j.jval.2016.11.022.

  rakerr2

  February 1, 2017

• Rationale and study design of MOTION: A phase 4, prospective, single-arm, open-label study to measure outcomes in patients with pulmonary arterial hypertension not on active treatment.

  Mathai SC, Minai O, Sullivan SD, Lerner D, Levine D. Rationale and study design of MOTION: A phase 4, prospective, single-arm, open-label study to measure outcomes in patients with pulmonary arterial hypertension not on active treatment. Respir Med. 2017

  rakerr2

  January 1, 2017

• Longitudinal Evaluation of Work Status and Productivity After Bariatric Surgery.

  Alfonso-Cristancho R, King WC, Mitchell JE, Ramanathan R, Sullivan SD, Belle SH, Flum DR. Longitudinal Evaluation of Work Status and Productivity After Bariatric Surgery. JAMA. 2016 Oct 18;316(15):1595-1597. doi: 10.1001/jama.2016.12040.

  rakerr2

  October 18, 2016

• Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.

  Oster G, Sullivan SD, Dalal MR, Kazemi MR, Rojeski M, Wysham CH, Sung J, Johnstone B, Cali AM, Wei LJ, Traylor L, Anhalt H, Hull M, Van Vleet J, Meneghini LF. Achieve Control: A pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insu

  rakerr2

  October 3, 2016

• Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure.

  Bennette CS, Richards C, Sullivan SD, Ramsey SD. Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure. Health Aff (Millwood). 2016 May 1;35(5):805-12. doi: 10.1377/hlthaff.2015.1145.

  rakerr2

  May 1, 2016